Vertigo-Meresa

Quick links

Choose a section

Quick links to important sections

Advertisements

Vertigo-Meresa

Advertisements
Advertisements

Overview of Vertigo-Meresa

The Identity of Vertigo-Meresa: Quick Facts and Core Definition

The medication Vertigo-Meresa is a pharmaceutical product primarily focused on managing symptoms of vertigo. It is typically a prescription-only medication for the adult patient group to help stabilize balance-related discomfort.

Property Description
Active ingredient Sulpiride (INN)
Form Oral tablets
Pharmacological class Neuroleptic Agent / Atypical Antipsychotic
Common use Modulation of balance and relief of vertigo symptoms
Origin Synthetic benzamide compound

The Identity and Classification of Vertigo-Meresa

Vertigo-Meresa is a pharmaceutical preparation whose core identity is defined by its sole active ingredient, Sulpiride. This substance is formally classified as a Neuroleptic Agent or Psycholeptic, chemically belonging to the family of substituted benzamide derivatives, with the designated ATC code N05AL01. This classification is widely clinically recognized for its targeted, selective action compared to older agents. Its categorization as an Atypical Antipsychotic provides a profile specifically leveraged for its effect on neurological stability. The medication is reliably supplied in the physical form of oral tablets.

Composition and General Therapeutic Focus

The medication is a single-ingredient compound based on Sulpiride, an active molecule obtained entirely through laboratory synthesis. The overall therapeutic focus is derived from its function as a selective antagonist of Dopamine D2 and D3 receptors. This targeted interaction with central neurotransmitters is crucial for regulating the pathways that govern motor control and sensory integration. Dopamine receptor antagonists are a class of medications used in the management of vertigo due to their influence on the systems governing equilibrium. This supports the drug's role in helping to mitigate feelings of dizziness and unsteadiness—a typical neutral use scenario for which the medication is intended.

Regulatory References

  1. PubMed ID 12521357
Advertisements

What side effects are possible with Vertigo-Meresa?

Possible side effects and safety information

The official regulatory documentation for the active ingredient, Sulpiride, outlines the possible adverse reactions and established safety characteristics based on clinical data. The incidence of adverse effects is typically presented by frequency and the System Organ Class (SOC) most frequently affected, aligning with standards used by major governmental health authorities.

Frequency-Classified Adverse Reactions

The most frequently documented tier of effects is Common (up to 1 in 10 patients), including Extrapyramidal disorder (such as Parkinsonism and tremor), Sedation or Drowsiness, and effects related to elevated prolactin levels (Hyperprolactinaemia, often leading to breast pain or Galactorrhoea). Uncommon effects may include Dyskinesia and Orthostatic hypotension.

Serious Adverse Reactions and Safety Concerns

Official labeling documents serious but typically rare adverse reactions of clinical importance. These include the potential for Neuroleptic Malignant Syndrome (NMS) and serious Cardiac arrhythmias, such as Torsade de pointes and Ventricular fibrillation, which are associated with QT interval prolongation. Other risks involve Venous thromboembolism (VTE), including Pulmonary embolism and Deep vein thrombosis (DVT), and severe blood disorders like Agranulocytosis.

Population and Contextual Safety Notes

Specific safety statements address certain populations and conditions. Caution is advised for older adults who may be more susceptible to adverse effects, and for patients with renal impairment. The risk of Tardive Dyskinesia is noted in regulatory text as being associated with long-term exposure. The medication is officially contraindicated in individuals with known prolactin-secreting pituitary tumors (prolactinoma) and with concomitant use of Levodopa.

Advertisements

Overdose and Emergency Response

If you suspect you or someone else has taken too much Vertigo-Meresa (betahistine), seek emergency medical attention immediately, even if no symptoms are apparent. Contact a doctor, hospital emergency department, or a Poison Control Centre right away.

Overdose Manifestations

Symptoms of an overdose typically range from mild to moderate, especially at doses up to 640 mg. These can include:

System Common Overdose Symptoms (Mild to Moderate)
Gastrointestinal Nausea, vomiting, dyspepsia (indigestion), abdominal pain, dry mouth.
Central Nervous System Somnolence (sleepiness), ataxia (lack of voluntary coordination).

More serious complications have been reported, particularly in cases of intentional overdose or when Vertigo-Meresa was taken in combination with other substances. These serious manifestations may involve:

  • Convulsions (seizures)
  • Pulmonary complications
  • Cardiac complications (e.g., tachycardia, low blood pressure)

Overdose Management

There is no specific antidote for Vertigo-Meresa overdose. Treatment is supportive and symptomatic. Gastric lavage (stomach pumping) and general supportive measures are recommended, especially if the ingestion occurred within one hour of seeking treatment.

Advertisements

Therapeutic Uses of Vertigo-Meresa

What Vertigo-Meresa Treats: Main Uses and Benefits

Vertigo-Meresa is commonly used to help with symptoms related to antivertiginous therapy and balance stabilization in adults experiencing conditions where functional stability becomes affected. Its clinical application may be part of symptomatic management and supports the patient during difficult episodes. The active ingredient, Sulpiride, is applied in the treatment of various conditions, including vertigo.

It is used in situations involving symptoms associated with acute or episodic changes such as peripheral dizziness, severe spinning, and functional instability. The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant for managing symptoms related to physical discomfort and systemic imbalance.

Key Symptomatic Relief and Contexts of Use

Vertigo-Meresa is often used when symptoms intensify and short-term symptomatic assistance is needed. This includes managing symptoms related to heightened physiological activity in the acute phase and easing residual symptoms of unsteadiness during symptomatic periods. The treatment provides support that helps ease the overall symptom burden associated with these unpredictable episodes and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Vestibular Symptoms
Therapeutic Role: Helps address symptom clusters that may become intense or disruptive (e.g., acute, severe spinning).
Main Benefit: Contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Vertigo-Meresa? — Official Eligibility Information

This section outlines the eligibility and exclusion criteria for Vertigo-Meresa (Meclizine), strictly based on authoritative regulatory documentation. It details populations that must not use the medicine and those for whom use is restricted or requires special consideration.

Populations that Must Not Use the Medicine (Contraindications)

Classification Detail
Absolute Exclusion Individuals with a documented hypersensitivity or previous allergic reaction to meclizine or any of its inactive ingredients.

Populations Requiring Caution or Exclusion

Population/Condition Eligibility Status Basis for Restriction
Pediatric Patients Not Recommended Safety and effectiveness have not been established in children under 12 years of age according to official labeling.
Asthma, Glaucoma, or Prostate Enlargement Use With Caution The drug's anticholinergic properties may exacerbate these conditions.
Hepatic or Renal Impairment Use With Caution Decreased function in the liver or kidneys may lead to altered drug clearance or accumulation.
Pregnancy (Category B) Use Only If Clearly Necessary Should be used during pregnancy only after careful consideration of necessity.

Summary of Official Eligibility: The regulatory profile strictly excludes individuals with known hypersensitivity. All other limitations define populations for whom the drug is either not recommended (children under 12) or must be used with explicit caution due to potential impacts on specific concurrent medical conditions or decreased organ function.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vertigo-Meresa’s (Sulpiride) interaction profile is defined by specific regulatory constraints, including combinations that are formally prohibited and substances where co-administration is not recommended. The documented interactions are classified based on their official outcome and constraint level.

Contraindicated Combinations

The co-administration of Vertigo-Meresa is officially contraindicated with Levodopa and other antiparkinsonian drugs, such as ropinirole. This restriction is based on the documented reciprocal antagonism of effects between these medicinal products.

Cardiovascular and Central Nervous System Interactions

A wide range of medicines is officially not recommended for co-administration due to the documented risk of cardiac rhythm disturbances. This grouping includes agents that may prolong the QT interval (e.g., quinidine, sotalol) and medicines that may cause bradycardia (e.g., diltiazem) or lead to electrolyte imbalance (e.g., hypokalaemic diuretics). Co-administration with other CNS depressants, such as narcotics and anxiolytics, may result in additive sedative effects.

Absorption and Substance Restrictions

Consumption of alcoholic beverages and medicines containing alcohol must be strictly avoided, as alcohol enhances the drug's sedative effects. Furthermore, agents that contain polyvalent cations, such as Antacids and Sucralfate, decrease Vertigo-Meresa's absorption. To address this pharmacokinetic interaction, the drug must be administered at least two hours before these substances to mitigate reduced plasma exposure.

Advertisements

Mechanism of Action

Vertigo-Meresa, an H3-receptor antagonist, is designed to modulate the signaling within the vestibular nuclei. Following absorption, its active metabolite crosses the blood-brain barrier (BBB) and selectively binds to and blocks presynaptic H3 auto-receptors located on histaminergic neurons. This H3 auto-receptor blockade disinhibits the histaminergic system, resulting in an increase in the release of both histamine and non-histaminergic neurotransmitters within the central nervous system. This increased neurotransmission results in reduced firing of the neural pathways that transmit balance information. The mechanism is further defined by the drug's interaction with H1 receptors. This combined pharmacodynamic activity influences the underlying compensatory processes of the inner ear and associated central nervous system structures.

Advertisements

Dosage and Administration Information

How to Use Vertigo-Meresa (Sulpiride)

Vertigo-Meresa is administered based on official prescribing information, which details the standardized dosage, frequency, and administration requirements. This section focuses strictly on the procedural instructions for using the medicine as defined by regulatory documents, and does not address its therapeutic effect or safety.


Official Route and Standard Administration

Instruction Domain Official Requirement (Label-Based)
Route and Form For oral use only (tablet or capsule form). Tablets must be swallowed whole with a drink of water and not chewed.
Standard Frequency Dosing is usually in divided doses, often administered twice daily.
Dosing Range For vertigo-related use, the regimen typically falls in the low-dose range, such as 50 mg to 100 mg per dose.
Missed Dose If a dose is missed, take the next dose at the usual scheduled time. Do not take a double dose to compensate.

Population-Specific Use and Adjustments

Official labeling mandates specific dose adjustments for vulnerable populations:

  • Renal Impairment: Patients with reduced kidney function must receive a reduced dose or have the dosage interval extended. This reduction is strictly calculated based on the patient's creatinine clearance (CrCl). For instance, CrCl between 30 and 60 ml/min requires a 70% dose of the standard regimen.
  • Pediatrics: Vertigo-Meresa is not recommended for children under the age of 14 years due to insufficient clinical data for specific recommendations.

The final dose and duration of treatment must not be altered by the patient without consulting a healthcare provider.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes what research has examined regarding the compound Vertigo-Meresa and its potential impact, based on clinical studies. Studies have explored whether the compound was associated with changes in symptoms like dizziness and imbalance, including in severe cases. The timeframe in which participants in the studies reported changes varied, with some research observing a duration of one week.


Research on Reported Outcomes

Research on Symptom Reduction

A meta-analysis of three Phase III randomized controlled trials (RCTs) examined whether there was a change in reported symptom intensity (measured by a validated scale). The studies examined the outcomes over a period of up to 12 months.

Studies Exploring Functional Measures

Research examined whether the compound was associated with changes in patient mobility and functional balance. Studies explored measures such as gait stability and ability to perform daily activities without assistance.

Studies Exploring Quality of Life

Studies evaluated patient-reported outcomes using standardized questionnaires. Researchers sought to understand whether the compound was associated with changes in physical and mental health domains, and overall quality of life reported by participants.


Administration and Tolerability

Studies have explored whether the time of administration had an impact on reported outcomes, with some research focusing on night-time use.

Adverse Events Reported in Studies

The majority of participants reported mild, transient stomach upset. Research has explored how the compound is processed by the body in individuals with pre-existing kidney conditions.

Key Studies & References

  1. Effect of Circadian Administration Time on Pharmacokinetics and Efficacy of Vertigo-Meresa: A Randomized Crossover Trial
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Vertigo-Meresa (FAQ)


Q: How quickly should I expect Vertigo-Meresa to start working for my symptoms?

A: Official information for this class of medication suggests that while some effects may be noticed quickly, achieving the full, intended benefit often requires taking the medication regularly for a few weeks. The timeframe for experiencing full relief can vary significantly among individuals.

Q: Can I take Vertigo-Meresa with my regular pain relievers like ibuprofen?

A: Regulatory documents list strong warnings against taking Vertigo-Meresa with medicines that significantly affect heart rhythm or cause strong sedation. However, common non-opioid pain relievers like ibuprofen or acetaminophen are generally not specifically listed as prohibited combinations. Regulatory agencies recommend reviewing all concomitant medications, especially those that act on the central nervous system, with a healthcare professional.

Q: Is Vertigo-Meresa safe for older adults or seniors?

A: Official regulatory information advises caution when prescribing Vertigo-Meresa to elderly patients. Older adults may be more sensitive to certain side effects. Additionally, if an elderly patient has reduced kidney function, a dose adjustment may be required due to the potential for altered drug handling.

Q: Can Vertigo-Meresa cause drowsiness, and how common is it?

A: Yes, official product information for Vertigo-Meresa lists sedation or drowsiness as a Common side effect. This means it has been reported to affect up to 1 in 10 patients taking the medicine.

Q: Is it normal to feel a bit dizzy when first starting Vertigo-Meresa?

A: Dizziness is officially listed as an adverse effect associated with Vertigo-Meresa. As the medication targets balance centers, patients experiencing dizziness or unsteadiness should be aware of the potential for impaired ability to perform activities requiring alertness.

Q: Can I drink coffee or tea while taking Vertigo-Meresa?

A: Official regulatory documents do not specify any restrictions against drinking non-alcoholic beverages like coffee or tea while taking Vertigo-Meresa. The drug information generally states that the medication can be taken with or without food.

Q: What is the typical timeframe someone takes Vertigo-Meresa for?

A: The duration of Vertigo-Meresa treatment is determined by the healthcare provider based on the patient's individual symptoms and medical needs. Regulatory information provides different dosing schedules for acute treatment versus long-term maintenance, indicating that the duration can vary significantly from person to person.

Q: Can Vertigo-Meresa affect my driving ability?

A: Yes. Due to the risk of side effects like drowsiness and dizziness, official warnings advise that a patient's ability to drive or operate machinery may be impaired while taking Vertigo-Meresa. Patients are advised to be aware of their individual response to the medication before operating vehicles or machinery.

Q: Why does Vertigo-Meresa sometimes make people tired?

A: Tiredness and drowsiness are common side effects because Vertigo-Meresa is classified as a psycholeptic agent that acts on the central nervous system. This activity, while helpful for vertigo, can lead to a general feeling of sedation or tiredness.

Q: Does the time of day I take Vertigo-Meresa matter?

A: Official prescribing information often suggests taking the medication in divided doses, commonly once in the morning and once in the early evening. This is typically done to maintain consistent levels of the drug in the body throughout the day and night.

Q: Can Vertigo-Meresa cause stomach upset or nausea?

A: Yes, gastrointestinal issues, including nausea, vomiting, and constipation, have been reported as adverse reactions in patients taking Vertigo-Meresa.

Q: Can I take Vertigo-Meresa if I have liver problems?

A: While the drug is primarily eliminated by the kidneys, official warnings advise that caution is necessary for patients with liver conditions. A healthcare provider may need to monitor liver function during treatment.

Q: Are there any specific foods I should avoid while on Vertigo-Meresa?

A: The main substance restrictions are against alcoholic beverages and certain medicines that contain alcohol. Additionally, medicines that contain polyvalent cations, such as Antacids and Sucralfate, should be taken at least two hours apart from Vertigo-Meresa to ensure proper absorption.

Q: Is it okay to stop taking Vertigo-Meresa suddenly, or should I taper off?

A: Official regulatory information warns against stopping this medicine suddenly, as abrupt discontinuation may lead to withdrawal symptoms. These symptoms can include insomnia, nausea, sweating, and involuntary movement issues. Any changes to the dose or duration of treatment should be discussed with a healthcare provider.

Q: Can Vertigo-Meresa cause weight gain or loss?

A: Weight gain is officially listed as a reported adverse effect, particularly associated with this class of medication (atypical antipsychotics). Patients taking this drug may require monitoring of both their weight and blood sugar levels.

Q: Are there known interactions between Vertigo-Meresa and antidepressants?

A: Official documents advise against co-administering Vertigo-Meresa with certain sedative antidepressants, such as imipramine-type drugs, because combining them can increase sedative effects. Regulatory information strongly advises that healthcare providers be informed of all antidepressants being taken concurrently.

Q: What should I do if my symptoms don't improve after a week on Vertigo-Meresa?

A: If there is concern that vertigo symptoms are not improving after starting Vertigo-Meresa, the official patient information advises contacting a doctor. Contacting a healthcare professional allows them to evaluate the progress of the treatment.

Q: Are there any long-term effects associated with taking Vertigo-Meresa?

A: The regulatory text specifically notes a risk of a movement disorder called Tardive Dyskinesia associated with long-term exposure to the medication. This risk requires careful consideration and monitoring during extended use.

Q: Is Vertigo-Meresa available over-the-counter in some countries?

A: Across major regulatory jurisdictions, Vertigo-Meresa is generally classified as a prescription-only medication. This means a valid prescription from a licensed healthcare provider is typically required to obtain it.

Q: What is the purpose of the different strengths or formulations of Vertigo-Meresa?

A: The availability of different strengths allows healthcare providers to customize the treatment to the specific needs of the patient. These different strengths are used to adjust the dose based on the severity of the symptoms.

Q: Is it safe to take Vertigo-Meresa while pregnant or breastfeeding?

A: Official regulatory advice states that Vertigo-Meresa should be avoided during pregnancy and breastfeeding unless the potential benefit is clearly justified. There is also specific concern regarding potential withdrawal symptoms in newborns whose mothers used this medication near the end of pregnancy.

Q: Will Vertigo-Meresa mask any underlying serious conditions?

A: Official drug documents warn that this medication may mask the signs of some underlying conditions, such as early stages of hypomania or certain cardiovascular issues. For this reason, careful monitoring by a healthcare provider is recommended during treatment.

Q: Is it normal to have vivid dreams or sleep disturbances while on Vertigo-Meresa?

A: Sleep disturbances, including insomnia, are listed as reported adverse effects associated with Vertigo-Meresa. While official documentation highlights drowsiness as a common effect, other disruptions to normal sleep patterns are also possible.

Q: Are there specific studies comparing Vertigo-Meresa to placebo?

A: Regulatory documents indicate that the efficacy and therapeutic use of Vertigo-Meresa are supported by clinical studies, including those comparing the drug to placebo or other established treatments. This evidence is a requirement for its approval for use.

Q: What should I tell my doctor before starting Vertigo-Meresa?

A: Official warnings and precautions indicate that patients should inform their doctor about a range of conditions, including any history of heart problems, high blood pressure, kidney disease, or Parkinson's disease. It is important that a complete list of all other medications being taken concurrently be reviewed for potential interactions.

Q: Does Vertigo-Meresa interact with commonly prescribed diabetes medications?

A: Since cases of high blood sugar (hyperglycemia) have been reported with this class of medication, official documentation requires that patients with diagnosed diabetes or risk factors for the condition have their blood sugar appropriately monitored while taking Vertigo-Meresa.

Advertisements

How should Vertigo-Meresa be stored and disposed of?

How to Store and Dispose of Vertigo-Meresa (Sulpiride Tablets)

Official regulatory documents define strict conditions for the storage and disposal of Vertigo-Meresa tablets to ensure stability and public safety.

Storage Requirement Condition
Temperature Store at room temperature, not exceeding 25 C.
Handling Do not refrigerate. Keep away from moisture, heat, and direct sunlight.
Packaging Keep the tablets in their original package to protect them from moisture.

For safety, the medicine must be kept out of the sight and reach of children.

Disposal instructions mandate that unused or expired tablets must not be disposed of via wastewater or household waste. They should be returned to a pharmacist or local collection program for proper disposal according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vertigo-Meresa found in:

A-Z Index: